Pharmaceutical major Cipla Limited has announced the signing of definitive agreements to acquire 100% equity stake in Inzpera Healthsciences Limited, a company engaged in developing and marketing differentiated paediatric and wellness products. The announcement was made through a corporate filing with the Bombay Stock Exchange (BSE).
Under the agreement, Inzpera Healthsciences will become a wholly-owned subsidiary of Cipla upon completion of the transaction. The enterprise value of the deal is approximately Rs 120 crore, while the purchase consideration stands at around Rs 110.65 crore, subject to customary adjustments.
Founded in June 2016, Inzpera Healthsciences focuses on innovative solutions in the paediatric and wellness segments. The company reported a turnover of Rs 26.75 crore in FY 2024-25, compared with Rs 22.05 crore in FY 2023-24 and Rs 20.76 crore in FY 2022-23.
Cipla stated that the acquisition does not constitute a related-party transaction, and none of its promoter or promoter group entities have any interest in Inzpera. The completion of the acquisition is expected within one month from the date of signing or as mutually agreed between the parties.
The move reflects Cipla’s ongoing strategy to expand its presence in consumer health and paediatric care, building on its strong pharmaceutical portfolio.
